Background: Drug-Drug Interactions (DDIs) contribute to increased rate of morbidity and mortality increasing the need for intense monitoring of patient safety which can be achieved by detecting and preventing morbidities associated with DDIs. Objective and Methodology: The present work was a prospective study carried out for a period of six months, to assess the incidence of DDIs in patients admitted to the Department of General Medicine at a tertiary care hospital. Results: Prescriptions of 411 patients were analysed, out of which 165 (40.15%) prescriptions were identified with potential DDIs whereas clinical manifestations of actual DDIs were observed and reported in 23 (5.6%). A total of 657 DDIs were observed of which 6 (0.9%), 240 (36.5%), 374 (56.9%) and 33 (5.6%) were of contra indicated, major, moderate and minor severity respectively. Based on the mechanism 310 (47.2%) of the identified DDIs were pharmacodynamic and 243 (36.9%) were pharmacokinetic interactions. There was a positive correlation between the number of DDIs and risk factors such as length of hospital stay, number of drugs prescribed and co-morbidities. Conclusion: This study concludes that awareness on the most prevalent DDIs can help the practitioners to prescribe drugs with a low risk for DDIs and prevent the concomitant use of dangerous drug combinations.
INTRODUCTION
Drugs are intended to alleviate disease and improve the quality of life in patients. However, many drugs are reported to cause unwanted reactions ranging from mild rashes to severe adverse reactions with fatal outcomes. Due to the complexity of disease and its comorbidities, multi-drug therapy is the current practice which is found to be alarming as it may result in drug related problems. 1 Drug-drug interactions represent an important and widely under-recognized source of medication errors and is responsible for 23% of hospital admissions. 2 Rational drug utilization may facilitate global reduction in drug induced morbidity and mortality. 1 Prescriptions with polypharmacy need a thorough evaluation in order to avoid any chance of Drug Related Problems (DRPs) which might result in adverse drug reactions, therapeutic insufficiency and increase the healthcare expenses. The involvement of pharmacist in a health care system may prevent such DRPs. 3 Administration of two or more drugs may lead to interactions resulting in alteration of therapeutic response or unwanted effects which are not observed with either of the drugs when consumed alone. DDIs may be severe enough to warrant hospital admissions for patients who got it manifested. [4] [5] Ahmad et al, 2015 has reported 66% of DDIs in the Department of General Medicine at a tertiary care hospital in Karnataka. 6 Studies have confirmed polypharmacy as one of the major risk factor for the incidence of DDIs. 7 DDIs contribute 20-30% incidence of ADRs which may increase the chance of hospital admission or lengthen the hospital stay. 8 Bhagavathula et al, reported the occurrence of 40% DDIs in prescriptions with 5 drugs and 80% with 7 medications or more. 9 Healthcare organizations must focus on patient safety monitoring for improvised health delivery. The scarcity of national studies on drug interactions and indiscriminate use of drugs, highlight the need for more studies that may contribute for planning and formulation of public health policies in this field. 10 Therefore, the current study was taken up to improvise the patient safety by monitoring, identifying and preventing DDIs.
MATERIALS AND METHODS
It is a prospective study conducted to identify the DDIs in patients admitted to the Department of General Medicine at a tertiary care hospital, Bangalore and this study was conducted between January and June 2016. This study was approved Institutional Ethics Committee (IEC) of M.S. Ramaiah Medical College, Bangalore.
Data collection
The data were retrieved from case sheets, medication charts, laboratory reports and by conducting medication history interviews. The patient profile form was developed which included patient's demographics, history of medications and allergy, diagnosis and clinical laboratory values. DDI form included the details of DDIs with its classifications based on severity, documentation and mechanism. and Drugs.com. Further, DDIs were classified based on the type and severity of interaction as contraindicated, major, moderate and minor along with mechanism of interactions.
Statistical analysis
Association between factors such as length of hospital stay, number of drugs per prescription, number of comorbidities and DDIs were analysed by chi-square test using SPSS V 20 .
RESULTS
In this study, a total of 411patients were enrolled, out of which 243 (59.1%) were males and 168 (40.9%) were females ( Figure 1 ). The prescriptions of the enrolled patients were analysed and the maximum number of drugs per prescription of the study population was 22 and minimum number was 2. Among 411 prescriptions, 39 (9.5%) prescriptions were below 4 medications and 372 (90.5%) were above or equal to 4 medications. The result shows that many prescriptions followed polypharmacy. Among 411 prescriptions, 165 (40.1%) were observed with pDDIs and 23 (5.6%) showed actual DDIs respectively ( Figure 2 ). A total of 657 DDIs were identified in 188 prescriptions. Out of 188 prescriptions with DDIs 123 (65.4%) prescriptions were in the range of 1-3 DDIs followed by 37 (19.7%) in the range of 4-6 and 28 (14.9%) above 6 DDIs (Table 1) . 105(25.5%) DDIs were identified in male whereas 83(20.2%) were identified in female ( Table 2 ). DDIs were found to be highest among patients aged above 50 years, 106 (25.7%) followed by patients aged between 25-50 years, 62 (15.1%). The difference in proportion of incidence of DDIs with different age groups was statistically significant (p<0.05) ( Table 3 ). Majority of the study population had co-morbidities along with their primary diagnosis ( Figure 3 ). In this study, the identified DDIs were classified based on the severity, documentation and mechanism (Table 5, 6 and Figure 4 ). Among the 657 DDIs per prescription, 6 interactions (0.9%) came under the classification of contraindication, 240 (36.5%) fall under major severity, 374 (56.9%) were of moderate severity and 37 (5.6%) were of minor severity. 657 DDIs were analysed for their type or mechanism of interaction. Out of which, 310 were pharmacodynamic DDIs, 243 were pharmacokinetic DDIs. Out of 657 DDIs, 68 (10.4%) were excellent, 249 (37.9%) were good and 340 (51.8%) were fair based on documentation criteria. Mechanism of actual DDIs and most frequently identified pDDIs along with their manifested and anticipated effects are described in Table 7 and 8 respectively. Factors such as length of hospital stay, number of co-morbidities and number of drugs per prescription were analysed and a statistically significant association between occurrence of DDIs and their factors were noted ( Table 4 ).
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DISCUSSION
As the number of medications increase, the complexity of therapy also increases which could lead to DRP and further reduce the clinical outcome. Drug interactions are recognized as the most dangerous DRP. 11 In this study, majority of the population were males which was similar to a study conducted by Ahmed et al. (2015) . 6 and contrast to the study conducted by Mateti U et al. 12 In this study, majority of patients fall under the age group of 25-50 years. The mean age was 45.7 ± 19 years. The maximum and minimum age of patients were 88 years and 15 years rspectively. Cruciol-Souza et al. (2006) has reported in their study that the average age of inpatients was 52.7 ± 18.9 years ranging from 12 to 98 years. 8 Our study is online with the studies conducted by 9, 13, 14 In this study, there was no appreciable difference in proportion of DDIs among both the genders.
It was found that the maximum number of drugs per prescription was 22 and minimum was 2. Out of 411 prescriptions, 188 were found with The chi square statistic is 0.3758. The p-value is 0.828694. The result is not significant at p<0.05. The chi square statistic is 23.01. The p-value is 0.000126. The result is significant (p<0.05). 
CONCLUSION
Our study concludes that the incidence rate of DDIs is high at the study site. Majority of the patients received polypharmacy. The identified predictors responsible for DDIs were polypharmacy, age, duration of hospital stay and the number of comorbidities. Hence, it is important to develop a systemic approach to minimize the possible DDIs. Clinical relevance of certain DDIs might be because of their pharmacological actions. The clinical pharmacist is of prime importance to provide information for a better decision on therapy, improve quality of treatment and reduce risks in the patients. This study tries to put forward the common DDIs which we came across in tertiary care hospitals and this may be a forewarning to health care team about reactions that may occur due to an interaction, as well as provide a support material for physicians to choose an alternate therapy, dose adjustments and patient monitoring. Most often the consequences of DDIs can be managed by withdrawal of potential drugs, specific symptomatic treatments, using alternative drug or dose adjustments. Awareness on the most prevalent DDIs can help the practitioners prescribe drugs with a low risk for DDIs and thereby prevent the concomitant use of dangerous medication combinations.
LIMITATION
Long-time follow up of the patients was not possible because of which delayed onset DDIs could not be assessed.
